When was Pi-Cardia founded?

Pi-Cardia was founded in 2009 and raised its 1st funding round 7 years after it was founded.

Where is Pi-Cardia located?

Pi-Cardia is headquartered in Rehovot, Israel.

Who is the current CEO of Pi-Cardia?

Erez Golan of Pi-Cardia. They have also founded 1 company.

How many employees does Pi-Cardia have?

As of Aug 31, 2026, the latest employee count at Pi-Cardia is 96.

Is Pi-Cardia a funded company?

Pi-Cardia is a funded company, having raised a total of $40M across 4 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Jan 10, 2016.

When was the latest funding round of Pi-Cardia?

Pi-Cardia's latest funding was a $***** Series D round on Sep 01, 2026, with participation from 1 investor. Its primary sector is Cardiac and Vascular Disorders. Globally, the Cardiac and Vascular Disorders sector has seen $1.93B in funding in 2026 to date.

Where does Pi-Cardia rank among its competitors?

Pi-Cardia ranks 6th amongst 114 active competitors, of which 51 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was HighLife Medical, which secured $90M in Sep, 2026.

Who are the top competitors of Pi-Cardia?

Pi-Cardia's top competitors include Shockwave Medical, MicroPort CardioFlow Medtech Corporation and Cardiac Dimensions. Among them, HighLife Medical secured the most recent funding round in September, 2026.

Pi-Cardia - 2026 Company Profile, Team, Funding & Competitors

Company Details

Pi-cardia manufactures non-implant devices for valve repair. The product Leaflex provides lines that create separation between the calcium deposits on the two sides of the scoring line, in order to regain leaflets flexibility, allow their mobility and improve valve hemodynamics.

Website: www.pi-cardia.net/
Social
Email ID: *****@pi-cardia.net
Phone Number: +972 **********

Key Metrics

Founded Year

2009

Location

Rehovot, Israel

Stage

Series D

Total Funding

$40M in 4 rounds

Latest Funding Round

Series D, Sep 01, 2026, $*****

Investors

Clal Biotechnology Industries & 10 more

Ranked

6^th among 114 active competitors

Employee Count

96 as on Aug 31, 2026

Similar Companies

Shockwave Medical & 148 more

View Pi-Cardia's full profile

Pi-Cardia has raised a total funding of $40M over 4 rounds. Its first funding round was on Jan 10, 2016. Its latest funding round was a Series D round on Sep 01, 2026 for $*****. 1 investor participated in its latest round. Pi-Cardia has 10 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Pi-Cardia:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 01, 2026	2356104	Series D	3121478	9170533	9315766	6934878
Apr 20, 2020	7880049	Series D	8992315	6050032	4430349	Jacques Séguin
Dec 12, 2018	4897558	Series C	6584385	4105233	Clal Biotechnology Industries	7857068

Access funding benchmarks and valuations. Sign up today!

View details of Pi-Cardia's funding rounds and investors

The founders of Pi-Cardia are Eyal Kolka and Erez Golan. Erez Golan is the CEO of Pi-Cardia.

Here are the details of Pi-Cardia's key team members:

Eyal Kolka: Co-Founder of Pi-Cardia.
Contact Info: 1 email address
Erez Golan: Co-Founder & CEO of Pi-Cardia.
Contact Info: 1 email address

View details of Pi-Cardia's Founder profiles and Board Members

Pi-Cardia's employee count trend

Pi-Cardia has 96 employees as of Aug 26. Here is Pi-Cardia's employee count trend over the years:

Uncover Pi-Cardia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pi-Cardia include Shockwave Medical, MicroPort CardioFlow Medtech Corporation and Cardiac Dimensions. Here is the list of Top 10 competitors of Pi-Cardia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Shockwave Medical 2009, Santa Clara (United States), Acquired	Developer of cardiovascular balloon dilation catheters	$148M	Sofinnova Partners, Venrock & 9 others	65/100
2nd	MicroPort CardioFlow Medtech Corporation 2015, Pudong (China), Public	Developer of smart medical devices for patients with heart valve diseases	$132M	Lake Bleu Capital, CICC & 10 others	63/100
3rd	Cardiac Dimensions 2001, Kirkland (United States), Series E	Developer of invasive cardiac implants for heart failure	$261M	Life Sciences Partners, Lumira Ventures & 20 others	63/100
4th	Peijia Medical Technologies 2012, Suzhou (China), Public	Developer of medical devices for the treatment of cardiac and cerebrovascular diseases	$110M	Lilly Asia Ventures, SDIC Innovation & 9 others	63/100
5th	JenaValve Technology 2006, Irvine (United States), Acquired	Provider of pericardial transcatheter aortic valve replacement and delivery system	$364M	Sunstone, Valiance Asset Management & 19 others	62/100
6th	Pi-Cardia 2009, Rehovot (Israel), Series D	Developer of non-implant device for valve repair	$40M	Kreos Capital, Accelmed & 9 others	62/100
7th	Venus MedTech 2009, Hangzhou (China), Public	Transcatheter aortic valves	$37M	DCP, HongShan & 6 others	62/100
8th	CroiValve 2016, Dublin (Ireland), Series B	Early‑stage medical device company developing a minimally invasive transcatheter system for repairing tricuspid valve regurgitation	$52.1M	Irrus Investments, Halo Business Angel Network ... & 21 others	58/100
9th	TRiCares 2013, Aschheim (Germany), Series D	Developer of a minimally invasive tricuspid valve replacement system. This system is designed to treat tricuspid regurgitation, a serious heart condition, without the need for open-heart surgery. The company focuses on developing a safe and effective solution to address the limitations of existing treatment approaches. It is developing a catheter-based system for tricuspid valve replacement. The company's efforts include clinical trials and securing funding to support further development and clinical milestones.	$103M	415 CAPITAL, Lifeblood Capital & 10 others	58/100
10th	HighLife Medical 2010, Paris (France), Series C	Developer of trans-catheter mitral valve replacement system	$141M	Sofinnova Partners, Andera Partners & 15 others	57/100